PPARG and breast carcinoma: Therefore, maybe there are functional connections between BRCA1, PPARγ and PFKP in glycolysis system and PFKP inhibitor may have a potential effect on BRCA1 dysfunctional breast cancer patients who suffer from diabetes and need treatments with PPARγ agonists.